Claudia Sheinbaum's government also plans to increase production of generic medicines and supplies, mainly, by 15%.
Mexico will seek to attract US$2 billion in research for the pharmaceutical and medical device industry by 2030, President Claudia Sheinbaum announced. During the conference on Thursday, from the National Palace, the president assured that this plan has generated interest among participants in the sector, who have approached the Secretary of Health, David Kershenobich.
“In the pharmaceutical and medical device industry (the goal is) to attract US$2 billion in annual investment in clinical research, and many people have already approached us, especially the Secretary of Health, who is also a nationally and internationally recognized researcher,” he said.
This investment is well above the US$262 million annually allocated in 2017 to clinical research, according to data from the Federal Commission for the Protection against Sanitary Risks (Cofepris).
By 2024, this amount was US$200 million, according to data from the Mexican Association of Pharmaceutical Research Industries (AMIIF), which estimated that investment in clinical research has the potential to reach US$4 billion annually.
The Mexico Plan for 2030 also contemplates increasing by 15% the national production of generic medicines, supplies, packaging, labels, chemical drugs, machinery and medical devices and supplies.
The federal executive stressed that manufacturing these products in Mexico will directly benefit the national economy, as it will contribute to strengthening the local industry.
“This is not only a matter of allowing imports to be included in the trade balance we have with Asian countries, and particularly China, due to the strengthening of the trade agreement, but because it is what is best for us, for Mexico, to be able to have the production of all this in our country to strengthen our economy and, of course, the economy of which we are a part in the trade agreement,” he said.
The Plan Mexico document also contemplates private investment to build the first vaccine production plant with mRNA technology in Mexico, intended for national consumption and export.
In addition, as part of the strategy to strengthen self-sufficiency in health, the manufacture of vaccines made in Mexico will be promoted. Another objective is for the Federal Commission for the Protection against Sanitary Risks (Cofepris) to reduce to a maximum of 40 days the time to approve new clinical research, in order to attract more investments.
